PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer ; volume:28 ; number:1 ; day:9 ; month:6 ; year:2023 ; pages:1-12 ; date:12.2023
Journal of mammary gland biology and neoplasia ; 28, Heft 1 (9.6.2023), 1-12, 12.2023
- Urheber
-
Amante, Romain J.
Jehanno, Charly
Silva, Duvini De
Coissieux, Marie-May
Ackerknecht, Markus
Romanet, Vincent
Sethi, Atul
Hamelin, Baptiste
Preca, Bogdan-Tiberius
Piscuoglio, Salvatore
Ng, Charlotte K. Y.
Mohseni, Morvarid
Bentires-Alj, Mohamed
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10911-023-09539-9
- URN
-
urn:nbn:de:101:1-2023091909190658446549
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Amante, Romain J.
- Jehanno, Charly
- Silva, Duvini De
- Coissieux, Marie-May
- Ackerknecht, Markus
- Romanet, Vincent
- Sethi, Atul
- Hamelin, Baptiste
- Preca, Bogdan-Tiberius
- Piscuoglio, Salvatore
- Ng, Charlotte K. Y.
- Mohseni, Morvarid
- Bentires-Alj, Mohamed
- SpringerLink (Online service)
Ähnliche Objekte (12)
Metastatic Triple-Negative Breast Cancer
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Metastatic and triple-negative breast cancer: challenges and treatment options
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Practical consensus recommendations on management of triple-negative metastatic breast cancer
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer
SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer
Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase
WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer
Metastatic Triple-Negative Breast Cancer
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Metastatic and triple-negative breast cancer: challenges and treatment options
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Practical consensus recommendations on management of triple-negative metastatic breast cancer
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer
SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer
Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase
WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer
Metastatic Triple-Negative Breast Cancer
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Metastatic and triple-negative breast cancer: challenges and treatment options
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Practical consensus recommendations on management of triple-negative metastatic breast cancer
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer
SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer
Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase